Category Archives: Cancer and neoplasms

Castle Biosciences Announces Multiple Data Presentations at the 2023 American Society for Dermatologic Surgery Annual Meeting

Video abstracts reinforce the clinical validity and utility of the Company’s skin cancer test portfolio, including DecisionDx®-Melanoma, DecisionDx®-SCC and MyPath® Melanoma FRIENDSWOOD, Texas–(BUSINESS WIRE)– Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that data spanning its dermatologic portfolio of gene expression profile (GEP) tests was […]

MiR-200b categorizes patients into pancreas cystic lesion subgroups with different malignant potential

Abstract Extracellular vesicles (EV) carry their cargo in a membrane protected form, however, their value in early diagnostics is not well known. Although pancreatic cysts are heterogeneous, they can be clustered into the larger groups of pseudocysts (PC), and serous and mucinous pancreatic cystic neoplasms (S-PCN and M-PCN, respectively). In contrast to PCs and S-PCNs, […]

Racial disparities between measures of area deprivation and financial toxicity, and uterine volume in myomectomy patients

Stewart EA, Cookson CL, Gandolfo RA, Schulze-Rath R. Epidemiology of uterine fibroids: a systematic review. BJOG. 2017;124(10):1501–12. Article  CAS  PubMed  Google Scholar  Baird DD, Dunson DB, Hill MC, Cousins D, Schectman JM. High cumulative incidence of uterine leiomyoma in black and white women: ultrasound evidence. Am J Obstet Gynecol. 2003;188(1):100–7. Article  PubMed  Google Scholar  Kim […]

$72 Million Funds Neoantigen-based Cancer Vaccine Candidates

(Precision Vaccinations News) Nouscom recently announced the completion of its Series C equity financing, raising $72 million that will be used to continue advancing and expanding Nouscom’s wholly-owned clinical pipeline to achieve multiple clinical value catalysts. As of November 13, 2023, the funding proceeds will support the following initiatives: Readout from Nouscom’s ongoing randomized Phase 2 […]

Nouscom Raises €67.5 million ($72 million) in Oversubscribed Series C Financing Round

New specialist European and US life sciences investors join existing investors to enable Nouscom to continue advancing the clinical development of its portfolio of neoantigen cancer vaccines to key clinical proof of concept endpoints BASEL, Switzerland – 14th November 2023 – Nouscom, a clinical stage immuno-oncology company developing off-the-shelf and personalized viral vector-based cancer vaccines […]

‘I Was Able To Avoid Getting Pancreatic Cancer. For That, I Am Forever Grateful.’

By Guest Writer – November 13, 2023 Doctors discovered a cyst in the head of Valerie Breen’s pancreas while she was visiting Paris. Every year, I think of November as a month of Thanksgiving. For me, post Halloween and before Christmas, it’s a time to celebrate with a thankful heart. This November is even more […]

Bayer Withdraws US Indication for Copanlisib in Relapsed Follicular Lymphoma

Bayer has announced the intention to voluntarily withdraw the new drug application for copanlisib (Aliqopa) in adult patients with relapsed follicular lymphoma who have previously received at least 2 prior systemic treatments.1 In September 2017, the FDA granted accelerated approval to copanlisib for this population based on findings from the phase 2 CHRONOS-1 study (NCT01660451) […]

Queer Eye designer sets sights on rare blood cancer in GSK effort

Known for his work as the interior designer on the hit makeover show Queer Eye, Thom Filicia is now hoping to change people’s lives in another way: by partnering with GSK to roll out a campaign for myelofibrosis, a rare blood cancer. Launched Monday, the Mapping Myelofibrosis campaign is raising awareness of the disease — which […]

How common are benign surgeries after lung cancer screening?

Sunday, November 26 | 1:40 p.m.-1:50 p.m. | S4-SSCH02-5 | Room N228  At least 15% of surgeries after lung cancer screening are performed on benign lesions, a study to be presented Sunday afternoon has found. Lung cancer screening with low-dose computed tomography (LDCT) reduces lung cancer deaths, but it does produce some measure of false-positive results, explained […]